OpGen, Inc.

135 articles with OpGen, Inc.

• OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/11/2021

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its financial and operating results for the three and nine months ended September 30, 2021, and provided a business update.

• OpGen Appoints Albert Weber as Chief Financial Officer

  11/4/2021

  OpGen, Inc today announced the appointment of Albert Weber as OpGen’s new Chief Financial Officer and Managing Director of OpGen’s subsidiary Curetis GmbH effective January 1, 2022.

• OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock

  11/4/2021

  OpGen, Inc. announced it has scheduled a Special Meeting of stockholders for December 8, 2021 at 10:00 a.m., Eastern time, to approve its proposed increase of the number of authorized shares of common stock

• OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time

  10/28/2021

  OpGen, Inc. announced today that the Company will provide a business update and report its third quarter 2021 financial results after the close of the U.S. financial markets on Thursday, November 11, 2021.

• OpGen Subsidiary Ares Genetics Launches AREScloud

  10/21/2021

  OpGen, Inc today announced that its subsidiary Ares Genetics has commercially launched its AREScloud web application.

• OpGen Announces Closing of $15 Million Registered Direct Offering

  10/18/2021

  OpGen, Inc. today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor of 150,000 shares of convertible preferred stock

• OpGen Announces $15 Million Registered Direct Offering

  10/14/2021

  OpGen, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 150,000 shares of convertible preferred stock

• OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel

  10/4/2021

  OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that it has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the Acuitas® AMR Gene Panel, and is finalizing preparations for its swift commercial launch in the U.S.

• OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021

  10/4/2021

  OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the third quarter of 2021 was approximately $1.2 million, up from $1.1 million in the third quarter of 2020.

• OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel

  9/30/2021

  OpGen, Inc. announced today that it has initiated the clinical trial for its Unyvero Urinary Tract Infection (UTI) Panel, which allows testing for a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimens.

• OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia

  9/15/2021

  OpGen, Inc. today announced clinical data from an investigator-initiated and driven prospective randomized controlled multicenter study.

• OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/12/2021

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its financial and operating results for the three and six months ended June 30, 2021 and provided a business update.

• OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time

  8/4/2021

  OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2021 financial results after the close of the U.S. financial markets on Thursday, August 12, 2021.

• OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program

  8/3/2021

  OpGen, Inc. today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform.

• OpGen Announces Partial Adjournment of Annual Meeting

  7/7/2021

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that the Company resumed its partially adjourned 2021 annual stockholders meeting on July 7, 2021, solely with respect to Proposal 2 set forth in its Definitive Proxy Statement, dated April 26, 2021, relating to the increase in the Company’s authorized shares of common stock.

• OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AMR Gene Panel for Isolates Data Presented at World Microbe Forum

  6/30/2021

  OpGen, Inc. today announced prospective clinical data on the Unyvero LRT BAL presented during a webinar held on June 29, 2021, and data presented at the virtual World Microbe Forum, June 20-24, 2021.

• OpGen Group Company Ares Genetics Presents R&D Pipeline Updates

  6/28/2021

  OpGen, Inc . today announced that its subsidiary Ares Genetics presented an update on the company’s R&D pipeline during two virtual seminars held on May 22 and on May 24, 2021.

• OpGen Group Company Ares Genetics Presents at AWS and Twist Bioscience Webinars

  6/9/2021

  OpGen, Inc. announced that its subsidiary Ares Genetics, which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance, is developing a culture-free, genomic assay for comprehensive AMR surveillance.

• OpGen Announces Partial Adjournment of Annual Meeting for Proposal 2 with All Other Proposals Passed

  6/9/2021

  OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), today announced that the Company conducted its 2021 annual stockholders meeting (the “Annual Meeting”) and adjourned the meeting solely with respect to Proposal 2 set forth in its Definitive Proxy Statement (the “Proxy Statement”) filed with the Securities and Exchange Commission on April 26, 2021.

• OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland

  6/7/2021

  OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that it has submitted an updated 510 summary document to the U.S. FDA for its Acuitas AMR Gene Panel for Isolates.